Citius Pharmaceuticals CTXR 深 沪
等待开盘 09-18 09:30:00 美东时间
1.18
+0.010
+0.85%
华盛通- 最 高1.23
- 今 开1.19
- 成交量 19.48万股
- 最 低 1.1715
- 昨 收 1.17
- 总市值 1318.59万
- 52周最高 13.50
- 市盈率 静 --
- 换手率 1.74%
- 52周最低 0.65
- 委 比 87.30%
- 总股本 1117.45万
- 历史最高 137.25
- 量 比 1.03
- 振 幅 5.00%
- 历史最低 0.65
- 每 手 1
- 风险率 3.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Citius Oncology To Raise $9M In Registered Direct Offering Of 5.14M Shares At $1.75 Each, Plus Warrants For 5.14M Shares Exercisable At $1.84
Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), a late-stage biopharmaceutical company developing and
09-09 20:47
Citius Oncology prices $9 million offering; shares down over 5%
Citius Oncology (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (NASDAQ:CTXR), announced on Tuesday that it has entered into a securities purchase agreement with a single inst...
09-09 20:42
Citius Oncology Deploys AI Platform To Bolster Commercial Strategy Ahead Of LYMPHIR Launch
Proprietary model informs targeted sales and marketing strategies with feedback loop thataugments precision and impact of targeting and engagementCRANFORD, N.J., Aug. 22, 2025 /PRNewswire/ -- Citius Oncology, Inc.
08-22 20:49
美股大行评级 | 潜在涨幅95.33%！HC Wainwright & Co.上调Insmed目标价至240美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Insmed"买入"评级，目标价从120美元升至240美元；巴克莱：维持Transocean"超配"评级，目标价从3.5美元升至4美元
08-14 09:25
D. Boral Capital Maintains Buy on Citius Pharmaceuticals, Maintains $6 Price Target
D. Boral Capital analyst Jason Kolbert maintains Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy and maintains $6 price target.
08-14 00:16
Citius Pharma Q3 EPS $(0.80) Misses $(0.58) Estimate
Citius Pharma (NASDAQ:CTXR) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.58) by 36.75 percent. This is a 49.04 percent increase over losses of $(1.57) per share from
08-13 04:33
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results
Context Therapeutics reported Q2 2025 financial results with $83.5 million in cash and expects to fund operations into 2027. The company is advancing its T cell engaging bispecific antibody pipeline, including CTIM-76 and CT-95, with initial data expected in 2026. Notable updates include CT-95's first patient dosing and presentations at major oncology conferences. R&D expenses rose to $7.8 million due to pipeline expansion and higher personnel co...
08-06 20:11
Citius Oncology Announces Pricing of $9.0 Million Public Offering
CRANFORD, N.J., July 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: ...
07-16 21:15
Cencora distribution deal boosts Citius shares
Citius Pharmaceuticals (NASDAQ:CTXR) traded higher in the premarket on Tuesday after the company announced that its majority-owned subsidiary, Citius Oncology (NASDAQ:CTOR), reached a distribution ser...
07-15 20:56
Citius Oncology Partners With Cencora To Boost Commercial Launch And Distribution Of FDA-Approved Immunotherapy LYMPHIR
Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIR™CRANFORD, N.J., July 15, 2025 /PRNewswire/ --
07-15 20:35
